Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06615752 · ClinicalTrials.gov registry record · Phase 1

Green Tea and Quercetin in Combination With Docetaxel Chemotherapy in Castration-resistant Prostate Cancer Patients

A Phase 1 study of Metastatic Castration-Resistant Prostate Cancer (mCRPC), sponsored by Charles Drew University of Medicine and Science.

Recruiting
Registry status
Phase 1
Development phase
99
Enrollment target
1
Study location

NCT06615752 is a Phase 1 study of Metastatic Castration-Resistant Prostate Cancer (mCRPC) that is actively recruiting participants, run by Charles Drew University of Medicine and Science. The registered enrollment target is 99 participants, below the 407-participant average among 15 other Metastatic Castration-Resistant Prostate Cancer (mCRPC) trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06615752, a Phase 1 study of Metastatic Castration-Resistant Prostate Cancer (mCRPC), is actively recruiting participants, sponsored by Charles Drew University of Medicine and Science.

RECRUITING
Registry status
Phase 1
Development phase
99 participants
Enrollment target
1
Study location

Study Summary

The goal of this clinical trial is to find out if taking natural products green tea and quercetin along with docetaxel chemotherapy improves the therapy of advanced prostate cancer, i.e., metastatic castration-resistant prostate cancer (mCRPC). It will also learn about the safety of this combination. Researchers will compare green tea plus quercetin to a placebo (a look-alike substance that contains no drug) in combination with docetaxel to see if green tea and quercetin works to improve the therapeutic effect of docetaxel.

Conditions Studied

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Interventions

  • DRUG green tea and quercetin + docetaxel
  • DRUG Placebo + docetaxel

Study Locations (1)

California

  • Charles R. Drew University of Medicine and Science - Los Angeles

Trial Details

FieldValue
Enrollment Target 99 participants
Start Date 2026-03
Est. Completion 2029-02
Phase Phase 1

Sponsor

Charles Drew University of Medicine and Science

30 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06615752

The ClinicalTrials.gov registry entry for NCT06615752 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 99 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 407-participant average among 15 other Metastatic Castration-Resistant Prostate Cancer (mCRPC) trials with a reported enrollment target (76% lower). The listed sponsor is Charles Drew University of Medicine and Science, which has 30 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Metastatic Castration-Resistant Prostate Cancer (mCRPC) appearing as the primary indexed condition, and to 2 interventions - of which green tea and quercetin + docetaxel is the first listed.

NCT06615752 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT06615752 about?

NCT06615752 is a clinical study titled "Green Tea and Quercetin in Combination With Docetaxel Chemotherapy in Castration-resistant Prostate Cancer Patients". The goal of this clinical trial is to find out if taking natural products green tea and quercetin along with docetaxel chemotherapy improves the therapy of advanced prostate cancer, i.e., metastatic castration-resistant prostate cancer (mCRPC). It will also learn about the safety of this combination...

What is the current status of trial NCT06615752?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 99 participants. The study started on 2026-03. Estimated completion is 2029-02.

What conditions does trial NCT06615752 study?

This clinical trial studies the following conditions: Metastatic Castration-Resistant Prostate Cancer (mCRPC).

What interventions are being tested in trial NCT06615752?

The interventions under investigation include: green tea and quercetin + docetaxel (DRUG), Placebo + docetaxel (DRUG).

Who is sponsoring clinical trial NCT06615752?

This trial is sponsored by Charles Drew University of Medicine and Science, which has 30 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06615752 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.